Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)
(Stockholm, 23 August 2023) Asarina Pharma today releases its First Half-Year Report for 2023. In addition to the financial statements for H1/2023, the report includes updates on the company’s communication of the positive results for its Phase IIa study in Tourette syndrome, and on its ongoing partnering activities.
FINANCIAL SUMMARY
• Cash outflow maintained at modest level
• New R&D expenses to depend on partnership
• Cash position on 30 June at 4.7 MSEK – sufficient for ongoing partnering activities
SIGNIFICANT EVENTS DURING THE REPORTING PERIOD
FEBRUARY 1, 2023 Last Patient Last Visit in Phase IIa study of Sepranolone in Tourette Syndrome.
APRIL 1, 2023 Positive results from the study demonstrate that Sepranolone performs well in both its primary endpoint (reducing tic severity) and all secondary endpoints. Sepranolone maintained an impressive safety profile with no off-target CNS effects or systemic side effects observed.
MAY 19, 2023 Results presented at TicCon – the Tourette Association of America’s Virtual Research Symposium for senior scientists representing all research projects currently ongoing in Tourette therapies.
JUNE 7–9, 2023 Results presented at the 15th European Conference on Tourette Syndrome and Tic Disorders (ESSTS) by Consultant Neurologist Dr. Heidi Biernat, Principal Investigator in the study and Head of the Tourette Clinic at Bispebjerg University Hospital Copenhagen.
CEO STATEMENT HIGHLIGHTS
CEO Peter Nordkild: “At the beginning of April 2023, we announced positive results for Sepranolone in our Phase IIa trial in Tourette Syndrome, indicating that Sepranolone has the potential to become the first-line pharmaceutical treatment for Tourette patients who cannot manage their condition with behavioral therapy (CBIT) alone.
Sepranolone achieved the rare combination of good tic reduction, improved quality of life and a superior safety profile, free of the negative CNS side-effects prevalent with current antipsychotic treatments like the dopamine D2 antagonist Haldol, representing for many patients and their parents, for the first time, a safe and effective pharmaceutical treatment.
May-June saw a period of intensive action as we took our results out into the scientific, clinical and business world, presenting our data at a range of top-tier scientific and industry events. On 5 - 8 June, we attended BIO 2023 in Boston, USA, where we held meetings with more than 20 companies. Here we were encouraged to see awareness of, and keen interest in, Sepranolone amongst key players within neurology – again centered around its unique modality, IP position and safety profile”.
Read the full quarterly report here: https://asarinapharma.com/investors/financial-reports/